Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06184698

Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer

Liposomal Irinotecan + Leucovorin + 5-fluorouracil + Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer (IRIS)：a Multicenter, Single-arm, Prospective, Phase II Study

Sponsor: Hebei Medical University Fourth Hospital

Conditions Colorectal Cancer

Interventions 5-FU Bevacizumab LV liposomal irinotecan

Updated 4 times since 2024 Last updated: Oct 7, 2024 Started: Jan 1, 2024 Primary completion: Feb 1, 2026 Completion: Mar 1, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Colorectal Cancer and is currently actively recruiting participants. Hebei Medical University Fourth Hospital leads this study, which shows 4 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Nov 2024 — Present [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Sep 2024 — Nov 2024 [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
Jan 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hebei Medical University Fourth Hospital

Data source: Hebei Medical University Fourth Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shijiazhuang, China